(Q40070340)

17 September 2017

title

Biosimilars: illustration of scientific issues in two examples (English)

1 reference

17 September 2017

Richard G Wenzel

1

1 reference

17 September 2017

publication date

1 July 2008

1 reference

American Journal of Health-System Pharmacy

17 September 2017

published in

1 reference

17 September 2017

volume

65

1 reference

17 September 2017

issue

14 Suppl 6

1 reference

17 September 2017

page(s)

S9-15

1 reference

Shifting paradigms: biopharmaceuticals versus low molecular weight drugs

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Historical aspects of botulinum toxin: Justinus Kerner (1786-1862) and the "sausage poison".

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Functional repair of motor endplates after botulinum neurotoxin type A poisoning: biphasic switch of synaptic activity between nerve sprouts and their parent terminals.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Comparing two botulinum toxin type A formulations using manufacturers' product summaries

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Formation of neutralizing antibodies in patients receiving botulinum toxin type A for treatment of poststroke spasticity: a pooled-data analysis of three clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Recent advances in erythropoietic agents in renal anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have nonmyeloid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 microg every 2 weeks) in anemic patients with cancer receiving chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

A randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia in patients with breast, lung, or gynecologic cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Benefits associated with an early hemoglobin response to epoetin alfa therapy in the treatment of chemotherapy-related anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP080211

31 March 2020

Identifiers

DOI

10.2146/AJHP080211

1 reference

17 September 2017

1 reference